Anti-inflammatory effects of anti-platelet treatment in atherosclerosis

Current Pharmaceutical Design

Volumn 18, Issue 28, 2012, Pages 4311-4325

  Arazi, H Cohen ^a   Badimon, J J ^a  

^a FLENI   (Argentina)

Author keywords

Anti inflammatory; Antiplatelet; Atherosclerosis; Inflammation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CD40 LIGAND; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; PRASUGREL; RANTES; THROMBOCYTE FACTOR 4; TICAGRELOR; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CELL INTERACTION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; INFLAMMATORY INFILTRATE; LOADING DRUG DOSE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAST CELL; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; T LYMPHOCYTE; THROMBOCYTE FUNCTION; UNSTABLE ANGINA PECTORIS;

ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; BLOOD PLATELETS; HUMANS; INFLAMMATION; MACROPHAGES; MAST CELLS; PLAQUE, ATHEROSCLEROTIC; PLATELET AGGREGATION INHIBITORS; T-LYMPHOCYTES;

EID: 84866393224     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802481264     Document Type: Article

References (219)

1. Russell, R. Atherosclerosis - an inflammatory disease. N Eng J Med 1999; 340(2): 115-126
2. Stary HC, Chandler AB, Dismore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Comitee on Vascular Lesions of the Council on Atherosclerosis, American heart Association. Circulation 1995; 92: 1355-1374
3. Kovanen PT, Kaartinen M, Pavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosiono r ruptura in myocardial infarction. Circulation 1995; 95: 1084-1088
4. Hanson GK. Mechanism of diseases: Inflammation, atherosclerosis, and coronary artery disease. N Eng J Med 2005; 352: 1685-1695
5. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671
6. Mc Millan DE. Blood flow and the localization of atherosclerotic plaques. Stroke 1985; 16: 582-587
7. Butcher EC. Leukocyte-endothellial cell recognition: three (or more) steps to specifity and diversity. Cell 1991: 67: 1033-1036
8. Springer TA. Traffic signals for lynfocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-304
9. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu rev Immunol 2002; 20: 197-216
10. Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22.1547-1559
11. Miller YI, Chang MK, Binder CI, Shaw PA, Wiztum JL. Oxidised low density lipoprotein and innate immune receptors. Curr Opin Lipidol 14: 437-445
12. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune response. Annu Rev Immunol 2003; 21: 713-758
13. Hansson GK. Inflammation, aterosclerosis, and coronary artery disease. N Eng J Med 2005; 352: 1685-1695
14. Stemme S, Faber B, holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes form human atherosclerotic plaques recognize oxidized low density lipoprotein. Prc Nat Acad Sci USA 1995; 92: 3893-3897
15. Folcik VA, Aamir R, Cathcart MK. Cytokine modulation of LDL oxidation by activated human monocytes. Arterioscler Thromb Vasc Biol 1997; 17: 1954-1961
16. Hanson GK, Jonasson L, Seifert PS, Stemme S. Inmune mechanisms in atherosclerosis. Arteriosclerosis 1989; 9: 567-578
17. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417: 750-754
18. Letinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 2003; 14: 421-430
19. Huo Y, Ley KF. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 2004; 14: 18-22
20. Bombeli T, Schwartz BR, Harlan JM. Adhesion of activation platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1)αβ3, integrin, and GPIbβ. J Exp Med 1998; 187: 329-339
21. Podrz EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotipe. Natural Medicines 2007; 13(9): 1086-1095
22. Ombrello Ch, Block RC, Morrell CN. Our expanding view of platelet functions and its clinical implications. J of Cardiovasc Trans Res 2010; 3: 538-546
23. Linden MD, Jackson DE. Platelets: pleiotropic roles in atherogenesis and atherothrombosis. The Intern J of Biochemistry & cell biology 2010; 42: 1762-1766
24. Hou Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbates atherosclerosis in mice deficient in apoE. Nat Med 2003; 9(1): 61-67
25. Nassar T, Sachaias BS, Akkawi S, et al. Platelet factor 4 enhances the binding of oxided-low density lipoprotein to vascular wall cells. J Biol Chem 2003; 278(): 6187-6193
26. Hermann A, Rauch BH, Braun M, Schror W, Weber AA. Platelet CD40 ligand (CD40L)- subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82
27. Liu Y, Zhao F, Gu W, et al. The role of platelets GPIIb/IIIa and alphavbeta3 integrins during HELa cells adhesion, migration, and invasion to monolayer endothelium under static and dynamic shear flow. J Biomed Biotechnol 2009; 2009: 829243
28. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary síndromes: implications for plaque ruptura. Circulation 1994; 90: 775-778
29. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003; 59: 812-823
30. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Atheroscler Thromb Vasc Biol 2004; 24: 1359-1366
31. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372
32. Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol 2003; 41: 7S-14S
33. Kereiakes DJ. Adjuntive pharmacotherapy before percutaneous coronary intervention in non-st-elevation acute coronary syndromes: the role of modulating inflammation. Circulation 2002; 108(Suppl III): III22-III27
34. Anad SS, Yusuf S. C-reactive protein is a bystander of cardiovascular disease. Eur H J 2010; 31: 2092-2096
35. Ridker PM. High- sensitivity C-reactive protein: potential adjunt for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 973-979
36. Danesh J, Whincup P, walker M, et al. Low grade inflammation and coronary heart disease: prospective study and update meta-analysis. BMJ 2000; 321: 199-203
37. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
38. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C- reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-733.
39. Sattar N, Murray HM, McConnachie A, et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Eldery at Risk (PROSPER). Circulation 2007; 11: 981-989.
40. Gussekloo J, Schaap MC, Frohlich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc. Biol 2000; 20: 1047-1051.
41. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001; 32: 917-924.
42. Cao JJ, Thach C, Manolio TA, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Helth Study. Circulation 2003; 108: 166-170.
43. Bos MJ, Schipper CM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM. High serum C- reactive protein level is not an independent predictor for stroke; the Rotterdam study. Circulation 2006; 114: 1591-1598.
44. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J 2007; 28: 354-362.
45. Ridker PM, Stampfer MR, Rifai N. Novel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-2485.
46. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for health-care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
47. Kluft C. Identifying patients at risk of coronary vascular disease: the potential role of inflammatory markers. Eur Heart J 2004; 6(suppl C): C21-C27
48. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepis MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on thrombosis and disabilities angina pectoris study group. Lancet 1997; 349: 462-466
49. James SK, Armstrong P, Barnathan E, et al. and The GUSTO-IVACS Investigators. J Am Coll Cardiol 2003; 41: 916-924
50. Lindhal B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Eng J Med 2000; 343: 1139-1147
51. Liuzzo G, Biasucci LM, Rebuzzi AG, et al. Plasma protein acutephase response in unstable angina: possible role of chemokines and platelets. Circulation 2003; 107: 2670-2676
52. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Eng J Med 2002; 347: 5-12
53. Bisoendial RJ, Boekholdt M, Vergeer M, Stroes ESG, Kastelein JP. C-reactive protein is a mediator of cardiovascular disease. Eur Heart J 2010; 31: 2087-2091
54. Bodman-Smith KB, Melendez AJ, Campbell I, Harrison PT, Allen JM, Raynes JG. C-reactive protein-mediated phagocytosis and phospholipase D signalling through the high-affinity receptor for immunoglobulin G (FcΩRI). Immunology 2002; 107: 252-260.
55. Devaraj S, Du Clos TW, Jialal I. Binding and internalization of Creactive protein by FcΩ receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 2005; 25: 1353-1363.
56. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
57. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: Creactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-919.
58. Li L, Roumeliotis N, Sawamura T, Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein- induced endothelial dysfunction. Circ Res 2004; 95: 877-883
59. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783-1790.
60. Pasceri V, Willerson JT, Edward TH. Direct proinflammatory effect of c-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168
61. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between. C-reactive protein and cardiovascular disease. Circulation 2004; 109: 2058-2067.
62. Devaraj S, Yun JM, Adamson G, Galvez J, Jialal I. C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res 2009; 84: 479-484.
63. Bisoendial RJ, Kastelein JJ, Peters SL, et al. Effects of CRP- infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J Lipid Res 2007; 48: 952-960.
64. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C- reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-520.
65. Suh W, Kim KL, Choi JH, et al. C-reactive protein impairs angiogenic functions and decreases the secretion of arteriogenic chemocytokines in human endothelial progenitor cells. Biochem Biophys Res Commun 2004; 321: 65-71.
66. Cirillo P, Golino P, Calabro P, et al. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res 2005; 68: 47-55.
67. Devaraj S, Xu DY, Jialal I. C- reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398-404.
68. Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells. Evidence that C- reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 2005; 25: 2216-2221.
69. Montero I, Orbe J, Varo N, et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006; 47: 1369-1378.
70. Bisoendial RJ, Birjmohun RS, Akdim F, et al. C- reactive protein elicits white blood cell activation in humans. Am J Med 2009; 122: 582-589.
71. Muller K, Aichele S, Herkommer M, et al. Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 2010; 213: 256-262
72. Bhatt DL. Inflammation and restenosis: is there a link? Am heart J 2004; 147: 945-947
73. Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Luscher TF. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vascular Med 2007; 12: 113-122
74. Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
75. Fremes SE, Levington C, Naylor CD, Chen E, Christakis GT, Goldman BS. Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis. Eur J Cardiothorac Surg 1993; 7: 169-180
76. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS- 2: 10 year survival among patients with suspected acute myocardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both, or neither: the ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998; 316: 1337-1343
77. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-830.
78. Cains JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicentes trial. N Eng J Med 1985; 313: 1369-1375
79. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative study. N Eng J Med 1983; 309: 396-403
80. Theroux P, Oumet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Eng J Med 1988; 319: 1105-1111
81. Physician Health study
82. Women Heath St
83. Meta 2002 ATC
84. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomized trials. Lancet 2009; 373: 1849-1860
85. Undas A, Brumel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyong strictly antiplatelet actions. Blood 2007; 109: 2285-2292.
86. Shimokawa T, Smith WL,. Prostaglandin endoperoxide synthase: the aspirin acetylation región. J Biol Chem 1992; 267: 12387-12392
87. Reilly IA, Fitzgerald GA. Inhibition of Thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987: 69: 180-186
88. A comparison of two doses of aspirin (30mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke: the Dutch TIA Trial Study Group. N Eng J Med 1991; 325: 1261-1266
89. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007; 297: 2018-2024
90. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255-258
91. Jaffe EA, Weksler BB. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest 1979; 63: 532-535
92. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-1291
93. Weber AA, Zimmerman KC, Meyer-Kirchrath J, Schor K. Cyclooxigenase- 2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353: 900.
94. Awtry E. Loscalzo J. aspirin. Circulation 2000; 101: 1206-1218
95. Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation- induced endothelial dysfunction: a novel vasculo-protective action of aspirin- Circulation 2002; 105: 2600-2604
96. Husain S, Andrews NP, Mulcahy D, panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998; 97: 716-720
97. Rajavashisth TB, Andalibi A, Territo MC, Navab M, Fogelman AM, Lusis AJ. Induction of endothelial cell expression of granulocyte and macrophage colony stimulating factors by modified low density lipoproteins. Nature 1990; 344: 254-257
98. Ikonomidis I, Andreotti F, Economou E, Stefanadis Ch, Toutouzas P, Nihoyannopoulos P. Increased Proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100: 793-798
99. Ishibashi S, Inaba T, Shimano H, et al. Monocyte colony stimulating factor enhances cholesterol uptake and degradation of acetylated low density lipoproteins and cholesterol esterification in human monocyte derived macrophages. J Biol Chem 1990; 265: 14109-14117
100. Munn DH, Beall AC, Song D, Wrenn RW, Throckmorton DC. Activation-induced apoptosis in human macrophages: developmental regulation of a novel cell death pathway by macrophage colony stimulating factor and interferon g. J Exp Med 1995; 18: 127-136
101. Takemura R, Werb Z. Secretory products of macrophages and their physiological significance. Am J Physiol 1984; 246: C1-C9
102. Bauer J, Ganteer U, Geiger T, Jacobshagen U, Gilberto G. Regulation of interleukin-6 expression in cultured human blood monocytes and monocyte derived macrophages. Blood 1988; 72: 1134-1140
103. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin 6 levels in humans in vivo. Arthritis Rheum 1992; 35: 982-984
104. Gaetano G, Cerletti C, Deiana E, Latini R. Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction. Circulation 1985; 72: 1185-1193
105. Fuster V, Sweeny JM. Aspirin: A historical and contemporary therapeutic overview. Circulation 2011; 123: 768-778
106. Iyengar S, Rabbani LE. Beyong platelet inhibition: potential pleiotropic effects of ADP-receptor antagonists. J Thromb Thrombolysis 2009; 27: 3006-3306
107. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE): CAPRIE Steering Committee. Lancet. 1996; 348: 1329-1339
108. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment levation. N Engl J Med 2001; 345: 494-502.
109. Mehta SR, Yusuf S, Peters RJ, et al For the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358: 527-533
110. Steinhubl SR, Berger PB, Mann JT, Fry ET, DeLago A, Wilmer C. for the CREDO Investigators, Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420
111. Sabatine MS, Cannon CP, Gibson CM, et al, for the CLARITYTIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005; 352: 1179-1189
112. Chen ZM, Jiang LX, Chen YP, et al, for the COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet. 2005; 366: 1607-1621
113. Bhatt DL, Fox KA, Hacke W, et al. for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 1706-1717
114. Bhatt DL, Flather MD, Hacke W, et al for the CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49: 1982-1988
115. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896
116. Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-851
117. Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clinical Pharmacol Ther 73: 232-241
118. Klinkhardt U, Bauersachs R, Admas J, Graff J, Lindhoff-last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocytes aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003; 73: 232-241.
119. Diehl P, Olivier Ch, Halscheid Ch, Helbing T, Bode Ch, Moser M. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Basic Res cardiol 2010; 105: 379-387
120. Lin N, et al. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb Res 2003; 111: 165-170
121. Azar RR, Kassab RK, Zoghbi A, et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 2006; 151: 521e1-521e4
122. Quinn MJ, Bhatt DL, Zidar F, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J cardiol 2004; 93: 679-684
123. Vavuranakis M, Latsios G, Aggelis D, et al. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Clin Therap 2006; 28860-28871
124. Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor antagonist peptide-induced platelet activation in patients with an acute coronary síndrome. J Am Coll cardiol 2004; 43: 1982-1988
125. Harding SA, Sarma J, Din JN, Maciocia PM, Newby DE, Fox KAA. Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus. Heart 2006; 92: 1335-1337
126. Hobson AR, Qureshi Z, Banks P, Curzen NP. Effects of clopidogrel on "aspirin specific" pathways of platelet inhibition. Platelets 2009; 20(6): 386-390
127. Bhatt DL. Inflammation and restenosis: is there a link. Am Heart J 2004; 147: 945-947
128. Rudez G, Duckers HJ, Simoons ML. Clopidogrel and endothelial injury after percutaneous coronary interventions. J Am Coll cardiol 2010; 56(13): 1032-1033
129. Boss CJ, balakrishnan B, Jessani S, Blann AD, Lip GY. Effects of percutaneous coronary intervention on peripheral venous blood circulating endothelial cells and plasma indices of endothelial damage/dysfunction. Chest 2007; 132: 1920-1926
130. Kereiakes DJ. Adjunctive pharmacotherapy before percutaneous coronary intervention in Non-ST-elevation acute coronary syndromes: the role of modulating inflammation. Circulation 2003; 108 (suppl III): III22-III27
131. Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 2004; 25: 1679-1687
132. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll cardiol 1999; 34: 1512-1521
133. Gaspardone A, Crea F, Versaci F, et al. Predictive value of Creactive protein after succesful coronary-aretry stenting in patients with stable angina. Am J Cardiol 1998; 82: 515-518
134. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. J Am Coll Cardiol 2000; 35: 1535-1542
135. Frink RJ, Rooney PA Jr, trwbridge JO, Rose JP. Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial infarction. Br Heart J 1988; 59: 196-200
136. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary aretery stenting. Stent Anticoagulation Restenosis Study Investigators. N Eng J Med 1998; 339: 1665-1671
137. Dibra A, Mehilli J, Braun S, et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med 2003; 114: 715-722
138. Gaspardone A, Versaci F, Tomai F, et al. C-reactive protein, clinical outcome, and restenosis rates after implantation of different drug eluting stents. Am J Med 2006; 97: 1311-1316
139. Park DW, Yun SC, Lee JY, et al. C-reactive protein and risk of stent thrombosis and cardiovascular events after dru-eluting stent implantation. Circulation 2009; 120: 1987-1995
140. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420
141. Berglund U, Richter A. Clopidogrel treatment before percutaneous coronary intervention reduces adverse cardiac events. J Invasive Cardiol 2002; 14: 243-246
142. Assali AR, Salloum J, Sdringola S, et al. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abxicimab or tirofiban). Am J Cardiol 2001; 88: 884-886
143. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein: Am J Cardiol 2001; 88: 672-674
144. Metha SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533
145. Vivekananthan DP, Bhatt DL, chew DP, et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004; 94: 358-360
146. Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harders S. Cloppidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte adhesión and platelet dependent leukocyte activation. Clin Pharmacol Ther 2003; 73: 232-241
147. Vivekananthan DP, Bhatt DL, Chew DP, et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004; 94: 358-360
148. Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from CLEARPLATELETS 1b study. J Am Coll Cardiol 2006; 48: 2186-2191
149. Antonino MJ, Mahla E, Bliden KP, Tantry US, Gurbel PA. Effect of long term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary artery stenting. Am J cardiol 2009; 103: 1546-1550
150. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006; 55: 780-784
151. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with diabetes type 2 and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-2435
152. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90: 625-628
153. Meune C, Wahbi K, Fulla Y, et al. Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors. Eur J Heart Fail 2007; 9(2): 197-201
154. Willerson JT, Cable G, Yeh ETH on behalf of the PROCLAIM investigators. PROCLAIM. Pilot Study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low dose aspirin. Tex Heart Inst J 2009; 36(6): 530-539
155. Jenberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and lower rate of non-responders compared with clopidogrel in aspiri-treated patients with stable coronary artery disease. Eur Heart J. 2006; 27(10): 1166-1177
156. Brant JT, Payne CD, Wiviot SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am heart J 2007; 153(1): 66e-9-66e-16
157. Wiviot SD, Braunwald E, McCabe CH, Al. Prasugrel versus clopidogrel in patients with acute coronary síndromes. N Eng J Med 2007; 357(20): 2001-2015
158. Montalescot G, Wiviott SD, Brauwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38) double blind, randomized controlled trial. Lancet 2009; 373: 723-731
159. Wiviot SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel- Thrombolisis in Myocardial Infarction 38. Circulation 2008; 118(16): 1626-1636
160. Frelinger AL, Jakubowski JA, Li Y, et al. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: influence of other blood cells, calcium and aspirin. Thromb Haemost 2007; 98: 192-200
161. Koziac K, Sevigny J, Robson SC, et al. Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes. Thromb Haemost 1999; 82: 1538-1544
162. Jin RC, Voetsch B, Localzo J. endogenous mechanisms of inhibition of platelet function. Microcirculation 2005; 12: 247-258
163. Serebruany VI et al. Platelet inhibition with prasigrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting; the subset from the JUMBO study. Postgrad Med 2006; 82: 404-410
164. Braun OO, Johnell M, Varenhorst Ch, et al. Greater reduction of platelet activation markers and platelet monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost 2008; 100: 626-633
165. Davies SL. Ticagrelor. Drugs of Today 2010; 46(4): 243-250
166. Cannon CP, usted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first oral reversible adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST. segment elevation acute coronary syndrome: Primary results of the DISPERSE 2 trial. J Am Coll cardiol 2007; 50(19): 1844-1851
167. Husted S, Harrington RA, Cannon CP, Stotorey RF, Mitchell P, Emanuelson H. Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist vs clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. Int J Clin Pract 2009; 63(4): 667-670
168. Wallentin L, Becker RC, Budal A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Eng J Med 2009; 361(11): 1045-1057
169. Husted S, Storey RF, Harrington RA, et al. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol 2010; 33(4): 206-212
170. Schneider DJ. Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy. J Am Coll Cardiol 2011; 57(6): 1-2
171. Schneider DJ, Holmes CE, Taatjes-Sommer HS, Sobel BE. Contributions of young platelets and of previously activated platelets to platelet reactivity in patients with coronary artery disease. Thromb Res 2008; 121: 455-462
172. Keating FK, Fung MK, Schneider DJ. Induction of platelet white blood cell (WBC) aggregate formation by platelets and WBCs in red blood cell units. Transfusion 2008; 48: 1099-1105
173. PRISM
174. PRISM PLUS investigators. Inhibition of platelet glicoprotein IIb/IIIa receptor with tirofiban in unstable angina and non Q wave myocardial infarction: Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Eng J Med 1998; 338: 1488-1497
175. PURSUIT trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary síndromes. N Eng J Med 1998; 339: 436-443
176. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van der Werf F et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary stndromes: a meta-analysis of all major randomized clinical trials. Lancet 2002; 359: 189-198
177. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295: 1531-1538
178. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Eng J Med 2001; 344: 1895-18903
179. Tcheng JE, Kandzari DE, Grines CL, et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial. Circulation 2003; 108: 1316-1323
180. Schor K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 2003; 15(2): 71-80
181. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppress the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001; 104: 163-167
182. Merino A, Gaya A, Segura I, et al. Platelet aggregation inhibition blocks C-reactive protein and interleukin 6 (IL-6) elevation after the coronary angioplasty: effect of the -174G/C IL-6 gene polimorphism. Am J Cardiol 2004; 94: 1300-1303
183. Merino A, Segura I, Vidal B, et al. Eptifibatide blocks C-reactive protein increase after coronary angioplasty. J Am Coll Cardiol 2003; 41: 233A
184. Welt FG, Rogers SD, Zhang X, et al. GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40 L and RANTES after 'percutaneous coronary intervention: Catheter cardiovasc interv 2004; 61: 185-189
185. Ercan E, tengiz I, Duman C, Onbasili OA, Baris N. Effect of tirofiban on C-reactive protein in non-ST elevation myocardial infarction. Am heart J 2004; 147: E1
186. Akbulut M, Ozbay Y, Gundogdu O, et al. Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions. Curr Med res Opin 2004; 20: 1759-1767
187. Azar RR, Badaoui G, Sarkis A, et al Effects of tirofiban and statins on high sensitive C reactive protein, interleukin 6 and soluble CD40 ligand following percutaneous coronary intervention in patients with stable coronary artery disease. Am J Cardiol 2005; 95: 236-240
188. Moreno PR, Murcia AM, Palacios IF, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes melliyus. Circulation 2000; 102: 2180-2184
189. Kastrati A; Mehilli J, Schullen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Eng J Med 2004; 350: 232-238
190. Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol & ther 2002; 71(3): 176-185
191. Schneider DJ, Taajes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of a granule release by specific types of inhibitors of glycoprotein IIb IIIa. Cardiovasc Res 2000; 45: 437-446
192. Seshia PN, Kereiakes DJ, Vasudevan SS, et al. Activated monocytes induce smooth muscle cell death: rol of macrophage colony stimulating factor and cell contact. Circulation 2002; 105: 174-180
193. Michelson JK, Ali MN, Kleiman NS. Chimeric 7E3Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol 1999; 33: 97-106
194. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxigenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003; 73: 122-130
195. Macchi L, Christianens L, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet P1A1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003; 42: 115-119
196. Wurtz M, Grove EI, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibition in patients with coronary artery disease. Heart 2010; 96: 368-371
197. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxigenase inhibitors and the antiplatelet effects of aspirin. N Eng J Med 2001; 345: 1809-1817
198. Crescent M, cerletti C, de Gaetano G. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in vitro findings. Thromb Haemost 2007; 97: 1054-1056
199. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002; 88: 711-715
200. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005; 46: 986-993
201. Lordkipanidze M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur heart J 2007; 28: 1702-1708
202. Snoep JD, Hovens MM, Eikelboom JC, van der Bom JG, Huisman MV. Association of laboratory defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Int Med 2007; 167: 1593-1599
203. Brantmark B, wahlin-Boll E, Melander A. Biovailability of acetyl salicylic acid and salicylic acid from rapid and slow release formulations, and in combination with dipyridamol. Eur J Clin Pharmacol 1982; 22: 309-314
204. Autry EH, Localzo J. Aspirin. Circulation 2000; 101: 1206-1218
205. Perneby C, Wallen H, Rooney C, Fitzgerald D, Hjemdahl P. Dose and time dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-658
206. Evangelista V, Manarini S, Di Santo A, et al. De novo synthesis of cyclooxygenase 1 counteracts the suppresion of platelet thromboxane biosynthesis by aspirin. Circ res 2006; 98: 593-595
207. Lucas AR, Korol R, Pepine CJ. Inflammation in aterosclerosis: some thoughts about acute coronary síndromes. Circulation 2006; 113: e728-e732
208. Zimmerman NN, Gams S, Hohlfeld T. Aspirin in coronary artery bypass surgery: new aspects of an alternatives for an old antithrombotic agent. Eur Journal cardioth Surg. 2008; 34(1): 93-108
209. Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, Sideris G, Sollier CB, Drouet L. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb haemost 2011; 105: 336-344
210. Kaser A, Brandacher G, Steur W, et al. Interleukin 6 stimulates thrombopoiesis through thrombopoietin: role of inflammatory thrombocytosis. Blood 2001; 98: 2720-2725
211. Cohen Arazi H, Doyni D, Spampinato Yorcivia R, et al. Impaired anti-platelet effect of aspirin, inflammation and platelet turn-over in cardiac surgery. Interac Cardiovasc Thorac Surg 2010; 10: 863-867
212. Taylor DW, Barnett HJM, Haynes RB, et al. Low dose and high dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial. Lancet 1999; 353: 2179-2184
213. Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalycilic acid (aspirin). Its relation to metabolic control. Thromb Res 2004; 113: 101-113
214. Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic Effects of different aspirin dosing regimens in type 2 diabetes mellitus patient with coronary artery disease. Circ Cardiovasc Interv 2011; 4: 180-187
215. Bhatt DL, Flather MD, Hacke W, et al. for the CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49: 1982-1988.
216. Giorgi MA, Di Girolamo G, Gonzalez CD. Non responders to clopidogrel: pharmacokinetics and interactions involved. Expert Opinion Pharmacother 2010; 11(14)
217. Giorgi MA, Cohen Arazi H, Gonzalez CD, di Girolamo G. Expert Opinion Pharmacother 2011; 12(8): 1285
218. CURRENT OASIS 7 Investigators. Dose comparison of clopidogrel and aspirin in acute coronary syndromes. N Eng J Med 2010; 363(10); 930-942
219. Palmerini T, Barozzi Ch, Tomasi L, et al. A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/ day in patients with ST-segment elevation acute myocardial infarction and por responsiveness to clopidogrel: results from the DOUBLE study. Thromb Res 2010; 125: 309-314